株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

医療ラボ検査サービスの戦略・動向・予測:世界版

Medical Laboratory Testing Services. Strategies & Trends. Volume & Price Forecasts by Laboratory Department. 2016 to 2019 - Global Version

発行 Howe Sound Research 商品コード 345313
出版日 ページ情報 英文 309 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
医療ラボ検査サービスの戦略・動向・予測:世界版 Medical Laboratory Testing Services. Strategies & Trends. Volume & Price Forecasts by Laboratory Department. 2016 to 2019 - Global Version
出版日: 2016年10月17日 ページ情報: 英文 309 Pages
概要

当レポートでは、世界の臨床ラボ検査サービス市場について取り上げ、主要国および検査領域別の規模・価格・収益データを提供しており、市場における近年の動向、主要企業のプロファイルをまとめ、お届けいたします。

第1章 イントロダクション・市場定義

第2章 市場概要

  • 市場参入企業
  • 市場区分
  • 産業構造
  • 主要企業のプロファイル
  • 国・地域の多様性

第3章 市場動向

  • 成長促進因子
  • 成長抑制因子
  • 自動化
  • 環境・発展
  • 診断技術の開発

第4章 ラボ、分子診断およびゲノム検査の近年の動向

第5章 各国の市場規模:北米

  • 米国
    • 臨床化学:規模・価格・収益
    • 微生物学:規模・価格・収益
    • 血液学:規模・価格・収益
    • 解剖病理学:規模・価格・収益
    • 分子診断:規模・価格・収益
    • 全臨床検査:規模・価格・収益
    • 心臓バイオマーカー:規模・価格・収益
    • 分子診断、腫瘍学:規模・価格・収益
    • 分子診断、遺伝学:規模・価格・収益
  • カナダ

第6章 各国市場:欧州

  • フランス
  • ドイツ
  • 英国
  • スペイン
  • イタリア
  • ロシア
  • その他の欧州および旧ソ連

第7章 各国市場:アジア太平洋

  • 中国
  • 日本
  • 韓国
  • インド
  • オーストラリア
  • その他のアジア太平洋

第8章 各国市場:ラテンアメリカ・アフリカ・中東

  • ブラジル
  • メキシコ
  • その他のラテンアメリカ
  • アフリカ・中東

第9章 世界市場のサマリー

  • 世界市場

第10章 臨床ラボの将来

付録

参考文献

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

OVERVIEW:

A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. Learn all about it in this new report from Howe Sound Research. A range of dynamic trends are pushing market growth and company valuations. Trends like ......

  • changing demographics
  • emerging economies and global prosperity
  • biotechnology advances in genetics
  • pathogen evolution
  • climate change
  • globalization
  • automation

Exciting technical developments especially in the area of molecular diagnostics and pharmacogenomics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.

“Medical Laboratory Testing Services - Strategies & Trends - Volume & Price Forecasts by Laboratory Department - 2016 to 2019 - Global Version” provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions.

Order an Enterprise Version specifically customized for your organizations needs for distribution throughout your company.

Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges. Questions? Email us at service at howesoundresearch.com. We would be glad to let you know if we can be of help.

The report includes detailed breakouts for 15 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1. Introduction and Market Definition

  • 1.1. Introduction
  • 1.2. Market Definition
    • 1.2.1. Volumes
    • 1.2.2. Prices
    • 1.2.3. Revenue Market Size
  • 1.3. Methodology
    • 1.3.1. Authors
    • 1.3.2. Sources
  • 1.4. U.S. Medical Market and Clinical Laboratory Testing - Perspective
    • 1.3.1. U.S. Medicare Expenditures for Clinical Testing

2. Market Overview

  • 2.1. Market Participants
    • 2.1.1. Supplier/pharmaceutical
    • 2.1.2. Independent lab specialized/esoteric
    • 2.1.3. Independent lab national/regional
    • 2.1.4. Independent lab analytical
    • 2.1.5. Public National/regional lab
    • 2.1.6. Hospital lab
    • 2.1.7. Physician lab
    • 2.1.8. Audit body
  • 2.2. Market Segments
    • 2.2.1. Traditional Market Segmentation
    • 2.2.2. Laboratory Focus and Segmentation
  • 2.3. Industry Structure
    • 2.3.1. Hospital Testing Share
    • 2.3.2. Economies of Scale
    • 2.3.3. Physician Office Lab's
    • 2.3.4. Physician's and POCT
  • 2.4. Profiles of Key Companies
    • 2.4.1. Quest Diagnostics
    • 2.4.2. Laboratory Corporation of America
    • 2.4.3. Lifelabs Medical Laboratory Services
    • 2.4.4. ACM Medical Laboratory
    • 2.4.5. Spectra Spectra Laboratories, Inc.
    • 2.4.6. Bio-Reference Laboratories, Inc.
    • 2.4.7. Signal Genetics LLC
    • 2.4.8. CompuNet Clinical Laboratories, LLC
    • 2.4.9. Genzyme Corporation
    • 2.4.10. Sonic Healthcare Limited
    • 2.4.11. Exagen Diagnostics, Inc.
    • 2.4.12. Clongen Laboratories LLC
    • 2.4.13. Clinical Reference Laboratory, Inc.
    • 2.4.14. Rosetta Genomics Inc.
    • 2.4.15. Mid America Clinical Laboratories, LLC
    • 2.4.16. Alere Inc
    • 2.4.17. Caris Life Sciences, Inc.
    • 2.4.18. Psychemedics Corp.
    • 2.4.19. Aurora Diagnostics, LLC
    • 2.4.20. DL Reference Laboratory
    • 2.4.21. Myriad Genetics, Inc.
    • 2.4.22. Bioscientia Institut fuer Medizinische Diagnostik GmbH
    • 2.4.23. Acibadem Labmed Laboratory
    • 2.4.24. Claymon Biomnis Laboratories Ltd.
    • 2.4.25. Biomnis (France)
    • 2.4.26. The Doctor's Laboratory (Sonic Healthcare U.K.)
    • 2.4.27. Pathology Inc.
    • 2.4.28. Gribbles Pathology
    • 2.4.29. BP Lab
    • 2.4.30. Adicon Clinical Laboratories, Inc.
    • 2.4.31. Diagnósticos da América (DASA)
    • 2.4.32. Medicus Phillipines Inc.
    • 2.4.33. Kingmed Diagnostics
    • 2.4.34. Ascend Clinical, LLC
    • 2.4.35. Unilabs SA
    • 2.4.36. American Pathology Partners, Inc.
    • 2.4.37. Centrex Clinical Laboratories, Inc.
    • 2.4.38. Integrated Regional Laboratories, Inc.
    • 2.4.39. Vira Cor-Ibt Laboratories
    • 2.4.40. Clarient, Inc.
    • 2.4.41. Genomic Health, Inc.
    • 2.4.42. ARUP Laboratories, Inc.
    • 2.4.43. MEDTOX Scientific, Inc.
    • 2.4.44. Solstas Lab Partners
    • 2.4.45. Predictive Biosciences, Inc.
    • 2.4.46. Enzo Biochem, Inc.
  • 2.5. National and Regional Diversity

3. Market Trends

  • 3.1. Factors Driving Growth
    • 3.1.1. Impact of U.S. Health Reform (PPACA) on U.S. Market
    • 3.1.2. Understanding the Impact of Aging Population.
    • 3.1.3. Economic growth drives health spending.
    • 3.1.4. Point of Care Testing can increase demand
    • 3.1.5. Wellness concerns create growth
    • 3.1.6. Esoteric Testing Moving Mainstream
    • 3.1.7. Genetic Based Testing Creates New Department and New Discipline
  • 3.2. Factors Limiting Growth
    • 3.2.1. Lower costs trend to continue
    • 3.2.2. Economic or population contraction.
    • 3.2.3. Testing usage analysis curtailing growth.
    • 3.2.4. Wellness has a downside
    • 3.2.5. Test Displacement Impacts Important
    • 3.2.6. Point of Care Testing
  • 3.3. Automation
    • 3.3.1. Stranded LIMS Investment
    • 3.3.2. Software as a Service
    • 3.3.3. Physician Office and Access Systems
  • 3.4. Environment and Evolution
  • 3.5. Diagnostic Technology Development
    • 3.5.1. Next Generation Sequencing Fuels a Revolution
    • 3.5.2. Impact of NGS on pricing
    • 3.5.3. POCT/Self Testing Disruptive Force
    • 3.5.4. Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.5.5. CGES Testing, A Brave New World
    • 3.5.6. Molecular Diagnostics Technologies At The Forefront of Growth
    • 3.5.7. Biochips/Giant magneto resistance based assay

4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments

  • 4.1. Recent Developments - Importance and How to Use This Section
    • 4.1.1. Importance of These Developments
    • 4.1.2. How to Use This Section
  • 4.2. Quest Diagnostics to Acquire Clinical Laboratory Partners
  • 4.3. Illumina, Almac to Collaborate on NGS CDx Assays
  • 4.4. Rite Aid First U.S. Drugstore Chain to Offer Harmonyx Genetic Testing to Customers
  • 4.5. US Patent Awarded to Singulex for Expanded Use of Biomarkers
  • 4.6. Feds to scrutinize med tech Medicare reimbursement in fiscal 2016
  • 4.7. Trovagene's Urine-Based Liquid Biopsy Platform Shows Clinical Sensitivity of 93 Percent in Lung Cancer Study
  • 4.8. Roche Rapid Flu MDx Test Shown to Impact Patient Care in ER
  • 4.9. CareDx Mobilizing Response Team After CMS Initial AlloMap Pricing Threatens Business
  • 4.10. PTS Diagnostics' Patent Enforcement Against Jant Pharmacal Gains Momentum
  • 4.11. SeraCare Life Sciences Announces Early Access Programs for ctDNA and RNA Fusion Reference Materials
  • 4.12. Eurofins Acquires Diatherix to Strengthen Specialty Clinical Diagnostics Focus
  • 4.13. Abbott Laboratories to buy St. Jude Medical for $25 billion
  • 4.14. CombiMatrix Gets Serious About Potential M&A Options in Wake of $8M Offering
  • 4.15. Abbott to Acquire Alere, Becoming Leader in Point of Care Testing
  • 4.16. Achieving Dx Ambitions Key to Avant-Amarantus-Theranostics Merger
  • 4.17. LabCorp Agrees to Acquire Assets of Pathology Inc.
  • 4.18. NeoGenomics Completes Acquisition of Clarient, Inc.
  • 4.19. FDA Gets Pushback on Move to Regulate Lab Developed Tests
  • 4.20. Cancer Genetics, Inc. Announces Partnership with BARC Global Central Laboratory to Offer Comprehensive Clinical Trial and Companion Diagnostic Solutions for the Oncology Industry
  • 4.21. Theranos plans to close all its clinical labs and lay off about 340 workers
  • 4.22. Forte Capital Lowers stake in Laboratory Corp. of America Holdings
  • 4.23. The US Oncology Network Selects Myriad Genetics As Preferred Provider For Hereditary Cancer Testing
  • 4.24. Pyxant Labs Commences Clinical Laboratory Testing Services
  • 4.25. Viewics Launches Diabetes Management (vCAT), A Free Solution For Laboratories Providing Powerful Diabetes Population Management Analytics To Healthcare Organizations
  • 4.26. Alpha Genomix And Rx30 Partner To Provide Personalized Medication Therapy
  • 4.27. LabCorp Doubles The Testing Capacity Of Covance Central Laboratory In Geneva
  • 4.47. OpGen Files for IPO for up to $37M
  • 4.48. Transgenomic Closes Public Offering of Stock, Warrants
  • 4.49. Qiagen Discloses $114.2M Price Tag for Enyzmatics Acquisition
  • 4.50. Laboratory Corporation of America Holdings Full Year Results
  • 4.51. GenomeDx Biosciences Implements Clarity LIMS
  • 4.52. Merck Serono and Sysmex Inostics Announce Testing Center
  • 4.53. Lifecode Receives CAP Accreditation, Discloses Funding
  • 4.54. Baylor College of Medicin, Miraca Holdings finalize joint venture.
  • 4.55. 23andMe Gets FDA Clearance to Market Bloom Syndrome Carrier Test
  • 4.56. LabCorp to Buy Covance for $6.1 Billion to Add Drug R&D
  • 4.57. Trinity Biotech Revenues Grow by 15%
  • 4.58. Google's Latest Healthcare Initiative
  • 4.59. Trinity Biotech Announces US Clinical Trials
  • 4.60. Agena Bioscience Launches Smaller Format MassArray
  • 4.61. QuantRx® Biomedical Provides Update on Technological Progress
  • 4.62. The Journal of Molecular Diagnostics Publishes Special Article
  • 4.63. Caprion Licenses Indi's Xpresys as Part of Larger Clinical Push
  • 4.64. MDxHealth's ConfirmMDx Genes Detect Prostate Cancer
  • 4.65. Atossa Genetics Announces That Its Subsidiary The National Reference Laboratory for Breast Health Has Received Accreditation
  • 4.66. Nuclea Bio Plans Entry into Clinical Proteomics
  • 4.67. Personal Genome Diagnostics Aims for FDA Clearance
  • 4.68. Enzo Biochem Announces New Molecular Platform
  • 4.69. Multiplicom, Premaitha Develop CE-IVDs
  • 4.70. Regulating the Next Generation of Genetic Testing
  • 4.71. BioReference Laboratories, Inc. Launches an Advanced Tumor Sequencing Program
  • 4.72. Cytogenetics Become First Certified Lab to Offer Microarray Testing
  • 4.73. Results Support Clinical Validity of Quantose IGT(TM) Diabetes Test
  • 4.74. Accelerate Diagnostics' 2014 Revenues Rise Sharply
  • 4.75. NanoString's Q4 Revenues Jump 54 Percent
  • 4.76. New Aussie Firm Life Letters Launches Carrier, PGx Testing for Consumers
  • 4.77. HTG Molecular Reports 50 Percent Increase in 2014 Revenues
  • 4.79. LabCorp Posts 5 Percent Revenue Growth
  • 4.80. Genomic Vision, Quest Extend Pact for Molecular Combing Technology
  • 4.81. ACT Genomics Raises $8M in Private Funding Round
  • 4.82. NGS-based Cancer MDx Firm Lifecode Raises $20.5M, Receives CAP Accreditation
  • 4.83. Invitae Goes Public with $101.6M Offering
  • 4.84. Quidel Q4 Revenues Grow 27 Percent on Infectious Disease Sales
  • 4.85. Rosetta Signs Deal to Promote Precipio's Cancer Diagnostics
  • 4.86. Premaitha Iona NIPT Lands CE Mark
  • 4.87. Sera Increases Series B Round to $25M with $5M from Gates Foundation
  • 4.88. T2 Biosystems Inks $8.5M Lyme Disease Dx Deal with Canon US Life Sciences
  • 4.89. Invitae Amends IPO Filing Targeting up to $92.3M
  • 4.90. Biofortuna Closes $2.2M Funding Round
  • 4.91. Roche MDx Sales Help Drive 2014 Diagnostics Revenues up 3 Percent
  • 4.92. AltheaDx Increases Target Amount on Proposed IPO to $74.3M
  • 4.93. BioMerieux 2014 Revenues Increase 7 Percent
  • 4.94. Cypher Genomics and Sequenom Announce Development Agreement
  • 4.95. Abcam to Acquire Firefly BioWorks for $28M
  • 4.96. PerkinElmer Opens Medical Laboratory in China
  • 4.97. Human Longevity, Genentech Ink Deal to Sequence Thousands of Genomes
  • 4.98. GenMark Projects 52 Percent Growth in Q4 Revenues
  • 4.99. Amarantus Acquires DioGenix for up to $10.9M
  • 4.100. Roche to Invest up to $1.2B in Foundation Medicine, Take Majority Stake
  • 4.101. DiaCarta Raises $8M in Series A Round
  • 4.102. Epic Sciences' Cancer Dx Laboratory Receives CLIA Certification
  • 4.103. Adaptive Biotechnologies Acquires Sequenta
  • 4.104. Aegis Sciences Acquires MDx Firm Diagnovus

5. Country Market Sizes - North America

  • 5.1. United States of America
    • 5.1.1. Clinical Chemistry - Volumes, Prices, Revenues
    • 5.1.2. Microbiology - Volumes, Prices, Revenues
    • 5.1.3. Hematology - Volumes, Prices, Revenues
    • 5.1.4. Anatomic Pathology - Volumes, Prices, Revenues
    • 5.1.5. Molecular Diagnostics - Volumes, Prices, Revenues
    • 5.1.6. All Clinical Testing - Volumes, Prices, Revenues
    • 5.1.7. Cardiac Biomarkers - Volumes, Prices, Revenues
    • 5.1.8. Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 5.1.9. Molecular Diagnostic Genetics - Volumes, Prices, Revenues
  • 5.2. Canada
    • 5.2.1. Clinical Chemistry - Volumes, Prices, Revenues
    • 5.2.2. Microbiology - Volumes, Prices, Revenues
    • 5.2.3. Hematology - Volumes, Prices, Revenues
    • 5.2.4. Anatomic Pathology - Volumes, Prices, Revenues
    • 5.2.5. Molecular Diagnostics - Volumes, Prices, Revenues
    • 5.2.6. All Clinical Testing - Volumes, Prices, Revenues
    • 5.2.7. Cardiac Biomarkers - Volumes, Prices, Revenues
    • 5.2.8. Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 5.2.9. Molecular Diagnostic Genetics - Volumes, Prices, Revenues

6. Country Markets - Europe

  • 6.1. France
    • 6.1.1. Clinical Chemistry - Volumes, Prices, Revenues
    • 6.1.2. Microbiology - Volumes, Prices, Revenues
    • 6.1.3. Hematology - Volumes, Prices, Revenues
    • 6.1.4. Anatomic Pathology - Volumes, Prices, Revenues
    • 6.1.5. Molecular Diagnostics - Volumes, Prices, Revenues
    • 6.1.6. All Clinical Testing - Volumes, Prices, Revenues
    • 6.1.7. Cardiac Biomarkers - Volumes, Prices, Revenues
    • 6.1.8. Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 6.1.9. Molecular Diagnostic Genetics - Volumes, Prices, Revenues
  • 6.2. Germany
    • 6.2.1. Clinical Chemistry - Volumes, Prices, Revenues
    • 6.2.2. Microbiology - Volumes, Prices, Revenues
    • 6.2.3. Hematology - Volumes, Prices, Revenues
    • 6.2.4. Anatomic Pathology - Volumes, Prices, Revenues
    • 6.2.5. Molecular Diagnostics - Volumes, Prices, Revenues
    • 6.2.6. All Clinical Testing - Volumes, Prices, Revenues
    • 6.2.7. Cardiac Biomarkers - Volumes, Prices, Revenues
    • 6.2.8. Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 6.2.9. Molecular Diagnostic Genetics - Volumes, Prices, Revenues
  • 6.3. United Kingdom
    • 6.3.1. Clinical Chemistry - Volumes, Prices, Revenues
    • 6.3.2. Microbiology - Volumes, Prices, Revenues
    • 6.3.3. Hematology - Volumes, Prices, Revenues
    • 6.3.4. Anatomic Pathology - Volumes, Prices, Revenues
    • 6.3.5. Molecular Diagnostics - Volumes, Prices, Revenues
    • 6.3.6. All Clinical Testing - Volumes, Prices, Revenues
    • 6.3.7. Cardiac Biomarkers - Volumes, Prices, Revenues
    • 6.3.8. Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 6.3.9. Molecular Diagnostic Genetics - Volumes, Prices, Revenues
  • 6.4. Spain
    • 6.4.1. Clinical Chemistry - Volumes, Prices, Revenues
    • 6.4.2. Microbiology - Volumes, Prices, Revenues
    • 6.4.3. Hematology - Volumes, Prices, Revenues
    • 6.4.4. Anatomic Pathology - Volumes, Prices, Revenues
    • 6.4.5. Molecular Diagnostics - Volumes, Prices, Revenues
    • 6.4.6. All Clinical Testing - Volumes, Prices, Revenues
    • 6.4.7. Cardiac Biomarkers - Volumes, Prices, Revenues
    • 6.4.8. Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 6.4.9. Molecular Diagnostic Genetics - Volumes, Prices, Revenues
  • 6.5. Italy
    • 6.5.1. Clinical Chemistry - Volumes, Prices, Revenues
    • 6.5.2. Microbiology - Volumes, Prices, Revenues
    • 6.5.3. Hematology - Volumes, Prices, Revenues
    • 6.5.4. Anatomic Pathology - Volumes, Prices, Revenues
    • 6.5.5. Molecular Diagnostics - Volumes, Prices, Revenues
    • 6.5.6. All Clinical Testing - Volumes, Prices, Revenues
    • 6.5.7. Cardiac Biomarkers - Volumes, Prices, Revenues
    • 6.5.8. Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 6.5.9. Molecular Diagnostic Genetics - Volumes, Prices, Revenues
  • 6.6. Russia
    • 6.6.1. Clinical Chemistry - Volumes, Prices, Revenues
    • 6.6.2. Microbiology - Volumes, Prices, Revenues
    • 6.6.3. Hematology - Volumes, Prices, Revenues
    • 6.6.4. Anatomic Pathology - Volumes, Prices, Revenues
    • 6.6.5. Molecular Diagnostics - Volumes, Prices, Revenues
    • 6.6.6. All Clinical Testing - Volumes, Prices, Revenues
    • 6.6.7. Cardiac Biomarkers - Volumes, Prices, Revenues
    • 6.6.8. Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 6.6.9. Molecular Diagnostic Genetics - Volumes, Prices, Revenues
  • 6.7. Remainder of Europe and Former Soviet Union
    • 6.7.1. Clinical Chemistry - Volumes, Prices, Revenues
    • 6.7.2. Microbiology - Volumes, Prices, Revenues
    • 6.7.3. Hematology - Volumes, Prices, Revenues
    • 6.7.4. Anatomic Pathology - Volumes, Prices, Revenues
    • 6.7.5. Molecular Diagnostics - Volumes, Prices, Revenues
    • 6.7.6. All Clinical Testing - Volumes, Prices, Revenues
    • 6.7.7. Cardiac Biomarkers - Volumes, Prices, Revenues
    • 6.7.8. Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 6.7.9. Molecular Diagnostic Genetics - Volumes, Prices, Revenues

7. Country Markets - Asia Pacific

  • 7.1. China
    • 7.1.1. Clinical Chemistry - Volumes, Prices, Revenues
    • 7.1.2. Microbiology - Volumes, Prices, Revenues
    • 7.1.3. Hematology - Volumes, Prices, Revenues
    • 7.1.4. Anatomic Pathology - Volumes, Prices, Revenues
    • 7.1.5. Molecular Diagnostics - Volumes, Prices, Revenues
    • 7.1.6. All Clinical Testing - Volumes, Prices, Revenues
    • 7.1.7. Cardiac Biomarkers - Volumes, Prices, Revenues
    • 7.1.8. Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 7.1.9. Molecular Diagnostic Genetics - Volumes, Prices, Revenues
  • 7.2. Japan
    • 7.2.1. Clinical Chemistry - Volumes, Prices, Revenues
    • 7.2.2. Microbiology - Volumes, Prices, Revenues
    • 7.2.3. Hematology - Volumes, Prices, Revenues
    • 7.2.4. Anatomic Pathology - Volumes, Prices, Revenues
    • 7.2.5. Molecular Diagnostics - Volumes, Prices, Revenues
    • 7.2.6. All Clinical Testing - Volumes, Prices, Revenues
    • 7.2.7. Cardiac Biomarkers - Volumes, Prices, Revenues
    • 7.2.8. Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 7.2.9. Molecular Diagnostic Genetics - Volumes, Prices, Revenues
  • 7.3. South Korea
    • 7.3.1. Clinical Chemistry - Volumes, Prices, Revenues
    • 7.3.2. Microbiology - Volumes, Prices, Revenues
    • 7.3.3. Hematology - Volumes, Prices, Revenues
    • 7.3.4. Anatomic Pathology - Volumes, Prices, Revenues
    • 7.3.5. Molecular Diagnostics - Volumes, Prices, Revenues
    • 7.3.6. All Clinical Testing - Volumes, Prices, Revenues
    • 7.3.7. Cardiac Biomarkers - Volumes, Prices, Revenues
    • 7.3.8. Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 7.3.9. Molecular Diagnostic Genetics - Volumes, Prices, Revenues
  • 7.4. India
    • 7.4.1. Clinical Chemistry - Volumes, Prices, Revenues
    • 7.4.2. Microbiology - Volumes, Prices, Revenues
    • 5.1.3. Hematology - Volumes, Prices, Revenues
    • 7.4.4. Anatomic Pathology - Volumes, Prices, Revenues
    • 7.4.5. Molecular Diagnostics - Volumes, Prices, Revenues
    • 7.4.6. All Clinical Testing - Volumes, Prices, Revenues
    • 7.4.7. Cardiac Biomarkers - Volumes, Prices, Revenues
    • 7.4.8. Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 7.4.9. Molecular Diagnostic Genetics - Volumes, Prices, Revenues
  • 7.5. Australia
    • 7.5.1. Clinical Chemistry - Volumes, Prices, Revenues
    • 7.5.2. Microbiology - Volumes, Prices, Revenues
    • 7.5.3. Hematology - Volumes, Prices, Revenues
    • 7.5.4. Anatomic Pathology - Volumes, Prices, Revenues
    • 7.5.5. Molecular Diagnostics - Volumes, Prices, Revenues
    • 7.5.6. All Clinical Testing - Volumes, Prices, Revenues
    • 7.5.7. Cardiac Biomarkers - Volumes, Prices, Revenues
    • 7.5.8. Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 7.5.9. Molecular Diagnostic Genetics - Volumes, Prices, Revenues
  • 7.6. Rest of Asia Pacific
    • 7.6.1. Clinical Chemistry - Volumes, Prices, Revenues
    • 7.6.2. Microbiology - Volumes, Prices, Revenues
    • 7.6.3. Hematology - Volumes, Prices, Revenues
    • 7.6.4. Anatomic Pathology - Volumes, Prices, Revenues
    • 7.6.5. Molecular Diagnostics - Volumes, Prices, Revenues
    • 7.6.6. All Clinical Testing - Volumes, Prices, Revenues
    • 7.6.7. Cardiac Biomarkers - Volumes, Prices, Revenues
    • 7.6.8. Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 7.6.9. Molecular Diagnostic Genetics - Volumes, Prices, Revenues

8. Country Markets - Latin America, Africa & The Middle East

  • 8.1. Brazil
    • 8.1.1. Clinical Chemistry - Volumes, Prices, Revenues
    • 8.1.2. Microbiology - Volumes, Prices, Revenues
    • 8.1.3. Hematology - Volumes, Prices, Revenues
    • 8.1.4. Anatomic Pathology - Volumes, Prices, Revenues
    • 8.1.5. Molecular Diagnostics - Volumes, Prices, Revenues
    • 8.1.6. All Clinical Testing - Volumes, Prices, Revenues
    • 8.1.7. Cardiac Biomarkers - Volumes, Prices, Revenues
    • 8.1.8. Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 8.1.9. Molecular Diagnostic Genetics - Volumes, Prices, Revenues
  • 8.2. Mexico
    • 8.2.1. Clinical Chemistry - Volumes, Prices, Revenues
    • 8.2.2. Microbiology - Volumes, Prices, Revenues
    • 8.2.3. Hematology - Volumes, Prices, Revenues
    • 8.2.4. Anatomic Pathology - Volumes, Prices, Revenues
    • 8.2.5. Molecular Diagnostics - Volumes, Prices, Revenues
    • 8.2.6. All Clinical Testing - Volumes, Prices, Revenues
    • 8.2.7. Cardiac Biomarkers - Volumes, Prices, Revenues
    • 8.2.8. Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 8.2.9. Molecular Diagnostic Genetics - Volumes, Prices, Revenues
  • 8.3. Remainder of Latin America
    • 8.3.1. Clinical Chemistry - Volumes, Prices, Revenues
    • 8.3.2. Microbiology - Volumes, Prices, Revenues
    • 8.3.3. Hematology - Volumes, Prices, Revenues
    • 8.3.4. Anatomic Pathology - Volumes, Prices, Revenues
    • 8.3.5. Molecular Diagnostics - Volumes, Prices, Revenues
    • 8.3.6. All Clinical Testing - Volumes, Prices, Revenues
    • 8.3.7. Cardiac Biomarkers - Volumes, Prices, Revenues
    • 8.3.8. Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 8.3.9. Molecular Diagnostic Genetics - Volumes, Prices, Revenues
  • 8.4. Africa & The Middle East
    • 8.4.1. Clinical Chemistry - Volumes, Prices, Revenues
    • 8.4.2. Microbiology - Volumes, Prices, Revenues
    • 8.4.3. Hematology - Volumes, Prices, Revenues
    • 8.4.4. Anatomic Pathology - Volumes, Prices, Revenues
    • 8.4.5. Molecular Diagnostics - Volumes, Prices, Revenues
    • 8.4.6. All Clinical Testing - Volumes, Prices, Revenues
    • 8.4.7. Cardiac Biomarkers - Volumes, Prices, Revenues
    • 8.4.8. Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 8.4.9. Molecular Diagnostic Genetics - Volumes, Prices, Revenues

9. Global Market Summary

  • 9.1. Global Market
    • 9.1.1. Clinical Chemistry - Volumes, Prices, Revenues
    • 9.1.2. Microbiology - Volumes, Prices, Revenues
    • 9.1.3. Hematology - Volumes, Prices, Revenues
    • 9.1.4. Anatomic Pathology - Volumes, Prices, Revenues
    • 9.1.5. Molecular Diagnostics - Volumes, Prices, Revenues
    • 9.1.6. All Clinical Testing - Volumes, Prices, Revenues
    • 9.1.7. Cardiac Biomarkers - Volumes, Prices, Revenues
    • 9.1.8. Molecular Diagnostic Oncology - Volumes, Prices, Revenues
    • 9.1.9. Molecular Diagnostic Genetics - Volumes, Prices, Revenues

10. The Future of the Clinical Laboratory

Appendices

  • I. United States Medicare System: January 2015 Clinical Laboratory Fees Schedule - National Limit and Midpoint

Table of Tables

  • Table 1: Medicare Clinical Lab Expenditures Actual & Forecast 2004 to 2020 ($Billion)
  • Table 2: Market Players by Type
  • Table 3: Clinical Laboratory Departments and Segments
  • Table 4: Laboratory Management Focus - Different Approaches
  • Table 5: Key Segmentation Variables Going Forward
  • Table 6: Factors Affecting Local Clinical Testing Demand
  • Table 7: Seven Factors Driving Growth
  • Table 8: Six Factors Limiting Growth
  • Table 9: Key Diagnostic Laboratory Technology Trends
  • Table 10: Next Generation Sequencing Technologies - Speed and Cost
  • Table 11: Key Point of Care Testing Uses
  • Table 12: Clinical Application Areas for Molecular Diagnostics
  • Table 13: Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 14: Microbiology - Volume Price and Revenue Forecast
  • Table 15: Hematology - Volume Price and Revenue Forecast
  • Table 16: Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 17: Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 18: All Clinical Testing - Volume Price and Revenue Forecast
  • Table 19: Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 20: Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 21: Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 22: Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 23: Microbiology - Volume Price and Revenue Forecast
  • Table 24: Hematology - Volume Price and Revenue Forecast
  • Table 25: Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 26: Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 27: All Clinical Testing - Volume Price and Revenue Forecast
  • Table 28: Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 29: Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 30: Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 31: Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 32: Microbiology - Volume Price and Revenue Forecast
  • Table 33: Hematology - Volume Price and Revenue Forecast
  • Table 34: Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 35: Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 36: All Clinical Testing - Volume Price and Revenue Forecast
  • Table 37: Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 38: Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 39: Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 40: Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 41: Microbiology - Volume Price and Revenue Forecast
  • Table 42: Hematology - Volume Price and Revenue Forecast
  • Table 43: Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 44: Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 45: All Clinical Testing - Volume Price and Revenue Forecast
  • Table 46: Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 47: Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 48: Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 49: Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 50: Microbiology - Volume Price and Revenue Forecast
  • Table 51: Hematology - Volume Price and Revenue Forecast
  • Table 52: Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 53: Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 54: All Clinical Testing - Volume Price and Revenue Forecast
  • Table 55: Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 56: Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 57: Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 58: Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 59: Microbiology - Volume Price and Revenue Forecast
  • Table 60: Hematology - Volume Price and Revenue Forecast
  • Table 61: Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 62: Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 63: All Clinical Testing - Volume Price and Revenue Forecast
  • Table 64: Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 65: Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 66: Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 67: Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 68: Microbiology - Volume Price and Revenue Forecast
  • Table 69: Hematology - Volume Price and Revenue Forecast
  • Table 70: Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 71: Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 72: All Clinical Testing - Volume Price and Revenue Forecast
  • Table 73: Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 74: Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 75: Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 76: Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 77: Microbiology - Volume Price and Revenue Forecast
  • Table 78: Hematology - Volume Price and Revenue Forecast
  • Table 79: Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 80: Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 81: All Clinical Testing - Volume Price and Revenue Forecast
  • Table 82: Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 83: Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 84: Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 85: Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 86: Microbiology - Volume Price and Revenue Forecast
  • Table 87: Hematology - Volume Price and Revenue Forecast
  • Table 88: Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 89: Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 90: All Clinical Testing - Volume Price and Revenue Forecast
  • Table 91: Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 92: Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 93: Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 94: Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 95: Microbiology - Volume Price and Revenue Forecast
  • Table 96: Hematology - Volume Price and Revenue Forecast
  • Table 97: Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 98: Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 99: All Clinical Testing - Volume Price and Revenue Forecast
  • Table 100: Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 101: Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 102: Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 103: Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 104: Microbiology - Volume Price and Revenue Forecast
  • Table 105: Hematology - Volume Price and Revenue Forecast
  • Table 106: Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 107: Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 108: All Clinical Testing - Volume Price and Revenue Forecast
  • Table 109: Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 110: Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 111: Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 112: Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 113: Microbiology - Volume Price and Revenue Forecast
  • Table 114: Hematology - Volume Price and Revenue Forecast
  • Table 115: Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 116: Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 117: All Clinical Testing - Volume Price and Revenue Forecast
  • Table 118: Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 119: Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 120: Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 121: Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 122: Microbiology - Volume Price and Revenue Forecast
  • Table 123: Hematology - Volume Price and Revenue Forecast
  • Table 124: Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 125: Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 126: All Clinical Testing - Volume Price and Revenue Forecast
  • Table 127: Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 128: Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 129: Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 130: Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 131: Microbiology - Volume Price and Revenue Forecast
  • Table 132: Hematology - Volume Price and Revenue Forecast
  • Table 133: Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 134: Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 135: All Clinical Testing - Volume Price and Revenue Forecast
  • Table 136: Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 137: Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 138: Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 139: Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 140: Microbiology - Volume Price and Revenue Forecast
  • Table 141: Hematology - Volume Price and Revenue Forecast
  • Table 142: Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 143: Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 144: All Clinical Testing - Volume Price and Revenue Forecast
  • Table 145: Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 146: Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 147: Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 148: Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 149: Microbiology - Volume Price and Revenue Forecast
  • Table 150: Hematology - Volume Price and Revenue Forecast
  • Table 151: Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 152: Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 153: All Clinical Testing - Volume Price and Revenue Forecast
  • Table 154: Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 155: Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 156: Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 157: Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 158: Microbiology - Volume Price and Revenue Forecast
  • Table 159: Hematology - Volume Price and Revenue Forecast
  • Table 160: Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 161: Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 162: All Clinical Testing - Volume Price and Revenue Forecast
  • Table 163: Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 164: Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 165: Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 166: Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 167: Microbiology - Volume Price and Revenue Forecast
  • Table 168: Hematology - Volume Price and Revenue Forecast
  • Table 169: Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 170: Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 171: All Clinical Testing - Volume Price and Revenue Forecast
  • Table 172: Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 173: Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 174: Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 175: Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 176: Microbiology - Volume Price and Revenue Forecast
  • Table 177: Hematology - Volume Price and Revenue Forecast
  • Table 178: Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 179: Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 180: All Clinical Testing - Volume Price and Revenue Forecast
  • Table 181: Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 182: Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 183: Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 184: Clinical Chemistry - Volume Price and Revenue Forecast
  • Table 185: Microbiology - Volume Price and Revenue Forecast
  • Table 186: Hematology - Volume Price and Revenue Forecast
  • Table 187: Anatomic Pathology - Volume Price and Revenue Forecast
  • Table 188: Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 189: All Clinical Testing - Volume Price and Revenue Forecast
  • Table 190: Cardiac Biomarkers - Volume Price and Revenue Forecast
  • Table 191: Molecular Diagnostic Oncology - Volume Price and Revenue Forecast
  • Table 192: Molecular Diagnostic Genetics - Volume Price and Revenue Forecast
  • Table 193: 2015 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1: Medicare Clinical Lab Expenditures 2004 to 2020 ($Million)
Back to Top